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This literature review addresses the subject of non-small-cell lung carcinoma (NSCLC) and the 
current treatments for it. For therapeutic purposes, lung carcinomas are histologically grossly 
organized into two main groups that are NSCLC and small-cell lung carcinoma (SCLC). 
NSCLC comprises about 85% of all lung carcinoma cases and are further organized into three 
histologic subgroups: squamous-cell carcinoma, adenocarcinoma, and large-cell lung cancer. 
Smoking status and mortality rates have been widely documented to have a correlation with all 
lung cancers. 
 
Diagnostical tools have improved and are sufficient to establish an accurate diagnosis without 
the need to rely on immunocytochemical or immunohistochemical analysis on routine basis. 
Despite these advanced tools and benefits of receiving early intervention, NSCLC is often di-
agnosed late, which precedes poor prognosis. 
 
Lung cancer develops over long period of time and often presents itself with non-specific res-
piratory symptoms, such as coughing, shortness of breath and sometimes bloody sputum. With 
smokers already excessively represented in pulmonary diseases and simultaneously being the 
dominant bracket to develop NSCLC, some of the warning signs of this cancer might go 
unnoticed for longer period amongst them. 
 
Current treatment options include traditional cancer treatments such as surgery, radiotherapy, 
and chemotherapy. Emphasis on these has remained strong, but treatments have begun convert 
into new and more specific options. Combination therapies, targeted therapies and 
immunotherapies are increasingly used in late-stage disease. Lastly, we touch on the possibil-
ities of novel bacteria-based therapies for lung cancer. 
 
Keywords:  non-small-cell lung cancer, surgery, radiotherapy, chemotherapy, immunother-
apy, targeted therapy, bacteria-based therapy  
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1 Non-Small-Cell Lung cancer 
1.1 Overview 
During the 19th century, lung cancer in general and particularly primary lung cancer quickly 
rose from being a rare incidence to now leading the mortality charts among cancers worldwide. 
This disease has traditionally been more prevalent among the more developed countries for 
several reasons, which include early industrialization and subsequent deterioration of air qual-
ity, and the accumulation of wealth and the subsequent exposure to tobacco, the biggest risk 
factor of lung cancer. (Didkowska, et al., 2016) (1) 
 
Developed nations saw their golden age of tobacco consumption in the dawn of the 20th century 
and since peaking in the middle century, the incidence trend for the male population has leveled 
off, even reversed. Apart from a few countries, the incidence rate will continue to rise. This 
phenomenon can be attributed to several causes, including aging of population, particularly in 
wealthier countries, total increase in tobacco consumption and increased life expectancy. 
However, contributing to the latter notions, the focus of incidence will likely turn more towards 
developing nations. Annual deaths are expected to rise above 3 million until 2035, with total 
deaths also rising in developed countries despite the recent years decline in smoking in men 
and plateau in women. (Didkowska, et al., 2016) 
 
Carcinomas of the lung are a heterogenous set of diseases and from a histological perspective 
they are broadly divided into two categories, SCLC and NSCLC, of which the latter accounts 
for 85% of the cases and will be the focal point of this review. NSCLC can be divided into 
groups of histological subtypes of which the two most prevalent are lung adenocarcinoma 
(LUAD) and lung squamous-cell carcinoma (LUSC). This categorization not only differentiates 
these diseases by histology, but subtypes also differ in their tendency to etiological causes and 
mutational burden, which in return drastically changes the approach to treating them now and 
in the future. (Herbst, et al., 2018) 
 
Smoking is heavily associated with LUSC, while LUAD is the most common subtype among 
the never-smokers, a group which has many variations in the literature, but we decide to use 
the definition for people who have exposed themselves to less than 100 cigarettes during their 
lifetime, while everyone else will be referred as ever-smokers. LUAD in never-smokers has 
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been shown to have association with exposure to environmental pollutions, second-hand smok-
ing, and genetic susceptibility. It also appears to have higher prevalence amongst women, par-
ticularly in Asia. (Sun, et al., 2007) 
 
Concerted efforts to curb lung cancer must be focused on primary prevention. Secondary pre-
vention is not a desirable option even for the wealthier countries because of the high cost of 
treatment. For the time being, tobacco control seems to be the only serious and most effective 
global strategy to combat lung cancer, although wealthy countries might benefit from the im-
plementation of better and more accurate screening methods in the future. (Didkowska, et al., 
2016) 
 
Combating tobacco and producing better primary screening is only the foundation for the solu-
tion, and new diagnostical tools, further subtyping, and targeted therapies are under develop-
ment to improve clinical outcomes for the patients. Even though progress has been steadfast for 
the past 20 years and we have witnessed the advent of targeted therapies and immunotherapies, 
lung cancer still proves to be evasive and expensive medicine has only yielded mere months to 
overall survival (OS), thus providing only a partial remedy to the problem. Further research of 
the mechanisms of tumor resistance to targeted therapy and better predictors of effectiveness 
of a given drug is needed to make sound decisions to concentrate the right therapies to the right 
populations that are likely to benefit from them. (Herbst, et al., 2018) 
 
Lung cancer remains deadly across the world. Reviewed survival data of some 5,3 million pa-
tients found the age-standardized 5-year net survival to generally stand in the range of 10-20% 
with only modest variability across different regions. (Allemani, et al., 2015) 
 
Despite the telling numbers in terms of incidence, mortality, and urgent need of improved treat-
ments, lung cancer research has long gone underfunded (Dela Cruz, et al., 2011). Interestingly, 
major funding has instead been funneled into less burdening cancer niches, such as leukemia. 





1.2 Risk factors 
1.2.1 Tobacco 
First notions of cause-effect of tobacco consumption and lung cancer were case reports pub-
lished in the 1930s, but it was only after two landmark studies published in 1950 that stood out 
with sufficient size, high response rates and clearly defined categories of smoking that serious 
research in this topic would gain interest (Doll & Hill, 1950, Wynder & Graham, 1950). Initial 
resistance was attributed to public and academic denial, for majority of male public and even 
physicians in the era were regular smokers (Thun, 2010). 
 
After 70 years of piling evidence, cigarette’s role in cancer development has been confirmed 
numerous times and since the inception of this notion, at least 50 carcinogens in tobacco fumes 
have been identified (Smith, et al., 2000a, Smith, et al., 2000b). 
 
Carcinogens contained in tobacco are associated with activating Kirsten Rat Sarcoma (KRAS) 
gene as well as inhibiting the tumor protein P53 (TP53) gene. Some of these mutations persist 
through time, which may partly explain the incidence of cancer years after smoking cessation 
in an individual. (Dela Cruz, et al., 2011) Smoking increases the relative risk 10- to 30-fold 
compared with lifetime never-smokers (Mattson, et al., 1987). However, while smoking in-
creases the likelihood of cancer to such extends, only one in 9 smokers eventually develop the 
disease, suggesting wider genetical susceptibility is probably included in the equation (Jemal, 
et al., 2005). 
 
1.2.2 Never-Smokers 
Never-smokers constitute a quarter of lung carcinoma cases, and as an independent subset rep-
resent the 7th most common cause of cancer deaths in the world. It is disproportionately more 
common in women, but geographical variability has also been shown, placing the emphasis in 
Asia. Plenty of unique attributes differentiates it from the lung cancer occurring in ever-smok-
ers. Cancers arising in never-smokers tend to occur more frequently in the distal airways and 
present LUAD histology. Molecular epidemiologic studies suggest different mutational ten-
dency as opposed to cancer in ever-smokers. These different molecular patterns make lung can-
cer in never-smokers more vulnerable to certain targeted therapies. (Sun, et al., 2007) 
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Relative importance of various risk factors, such as radon exposure in homes, second-hand 
smoke, such as combustion, have not been clearly defined worldwide. Overall lung cancer in 
never-smokers differs from that in ever-smokers in terms of tumor biology, prognosis, and re-
sponse to therapy, but more research in this field is needed. (Rudin, et al., 2009) 
 
1.2.3 Other 
Fine particles with diameter of 2.5μm or less (PM2.5) have been shown to increase risk for lung 
cancer when continuous chronic exposure is present. In a 26-year follow-up study, every 
10µg/m3 increase in PM2.5 concentration was associated with 15-27% increase in lung cancer 
mortality. (Turner, et al., 2011) 
 
Cancer susceptibility is partly determined by genetic factors, although the risk is mostly realized 
if person is an ever-smoker. Other risk factors include pulmonary fibrosis, human immunode-
ficiency virus infection and alcohol. (Duma, et al., 2019) One meta-analysis comprising of 32 
studies estimated that having a family history of lung cancer doubles the risk. Elevated risk was 
also seen in never-smokers. (Matakidou, et al., 2005) 
 
Estimates show that 10% of men and 5% of women lung cancer deaths can be connected to 8 
carcinogens that classify as occupational exposure, they are asbestos, arsenic, beryllium, cad-
mium, chromium, nickel, silica, and diesel fumes. Ionizing radiation has also been proved to be 
carcinogenic factor. Other factors such as gender, age and ethnicity also affect one’s risk, but 
will not be covered in this review. (Dela Cruz, et al., 2011) 
 
1.3 Diagnosis & classification 
One of the biggest challenges in dealing with lung cancer and adding to mortality and financial 
burden, is the elusiveness of the disease in its initial stage. Gradual, but slow progression and 
non-specific symptoms make all the difference, for majority of lung cancers commonly presents 
with little to no symptoms. Often the tumor is found at an advanced stage, which significantly 
lower the prognosis. (Mäkitaro, 2007) 
 
Symptoms are most commonly sign of late-stage disease and in their own remain highly unspe-
cific to this disease. Different presentations derive from several causes. The obstruction of nor-
mal anatomy in the lungs due to primary tumor can cause cough, bloody sputum, recurrent 
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pneumonia, shortness of breath, atelectasis, and stridor. Dyspnea can be caused by a tumor 
growing near phrenic nerve supplying the diaphragm. Mediastinal growth can damage the re-
current nerve, causing voice hoarseness or problems in swallowing. Other novel presentations 
include vena cava syndrome, shoulder-arm pain, Horner’s syndrome, and bone destruction. 
(Mäkitaro, 2007) 
 
Sometimes first signs are the ones attributed to metastases affecting other organs. Metastases 
in the liver can cause abdominal pain and elevation in liver enzymes, albeit this usually requires 
the tumor to have grown radically in size. Neurological symptoms such as headache, vertigo, 
nausea, seizures, or deficits in sensory or motoric capabilities might be evident if central nerv-
ous system is affected. Metastases in the bone can cause pain or pathological fractures. Despite 
all the possible organ-specific symptoms, sometimes only non-specific constitutional symp-
toms, such as fever, decreased appetite, weight-loss or malaise are the only clues present. 
Furthermore, an abnormal chest radiograph, accompanied with or without symptoms, can make 
a suspect and proceed to further evaluation. (Mäkitaro, 2007, Rivera, et al., 2013). 
 
Diagnosis will be confirmed through biopsy. Two kinds of biopsies are tissue biopsy, which 
are obtained by either bronchoscopy or surgical means, while cytological samples can be ac-
quired from effusion, aspiration, or by brushing. Morphologic evaluation is conducted next as 
it will guide the recognition towards diagnosis. Histological samples are stained with hematox-
ylin and eosin while cytological samples use giemsa staining. Sometimes clear characteristics 
might yield the immediate recognition as either LUAD or LUSC and further immunocytochem-
ical or immunohistochemical analysis is not needed. Should neuroendocrine features be present, 
sample can be classified as either SCLC or NSCLC. If there is no clear characteristics of LUAD 
or LUSC, the sample will be classified as NSCLC not otherwise specified (NOS). (Reck & 
Rabe, 2017) 
 
Further subdivision is accomplished by using immunocytochemical or immunohistochemical 
analysis, mucin staining, or molecular data. Classification for NSCLC favoring LUAD is de-
termined when sample tests positive for sarcolectin and NK2 homeobox 1, additionally LUSC 
markers must be negative. On the contrary, if sample tests positive for one or more LUSC 
leaning markers, such as p63, sex determining region Y-box 2, cytokeratin 5, or cytokeratin 6 
and negative for LUAD markers, NSCLC favoring LUSC is diagnosed. If none of the foremen-
tioned markers are positive, the sample is classified as NSCLC NOS. (Reck & Rabe, 2017) 
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One subtype of NSCLC includes large cell carcinoma, which is diagnosed by excluding LUSC 
and LUAD by histology and their specific markers. The literature is not decisive whether large 
cell carcinomas are distinct from LUSC or LUAD (Chen, et al., 2014, Pelosi, et al., 2015). 
 
Once diagnosis is established, further classification with molecular testing is recommended for 
those with non-LUSC NSCLC. The need for this approach is becoming ever more important as 
the number of treatable oncogenic alterations continues to expand. The list of potential treatable 
alterations continues to expand, but some of the most common articles to screen include muta-
tions in the genes encoding epidermal growth factor receptor (EGFR), v-Raf murine sarcoma 
viral oncogene homolog B (BRAF), anaplastic lymphoma kinase (ALK) and proto-oncogene 
tyrosine-protein kinase ROS (ROS1) genes. More recent example is assessing the expression of 
programmed death-ligand 1 (PD-L1), this marker is also assessed in LUSC. Algorithm for di-
agnostics of NSCLC is depicted below (Figure 1). (Reck & Rabe, 2017)  
 
The staging and histology of a tumor defines the treatment and prognosis of a given patient. 
The TNM Classification of Malignant Tumors (TNM), provided by the Union for International 
Cancer Control, is the international standard for tumor staging. Having its latest updates re-
leased in 2017, the current volume marks the 8th edition of its kind (Table 1). The section re-
garding lung cancer is maintained by the International Association for the Study of Lung Can-
cer. In the wake of personalized medicine, correct staging is at the very core of treatment. 
Correctly done analysis of the tumor will guide the therapy and monitor its effectiveness. 
(Detterbeck, et al., 2017) 






Initial estimation of tumor severity is clinical staging, which is accomplished by imaging. 
Computed tomography (CT) is considered the standard tool for staging. However, advance-
ments in technology, namely positron emission tomography (PET) and magnetic resonance im-
aging can offer improved accuracy in staging-phase. Utilizing fluorodeoxyglucose (FDG) in 
PET-CT has been shown to be better at assessing nodal status and disease than a regular contrast 
enhanced CT scan. FDG PET-CT scan can also determine occult carcinomas in the bone better 
than bone scan, as before changing the mineral composition of the cortical bone, new metasta-
ses initially affect the bone marrow, which is something the bone scan is unable to detect. (Reck 
& Rabe, 2017, Akhurst, 2018) 
 
Clinical staging alone is not sufficient for diagnosis. The ability of CT to detect mediastinal 
lymph node metastasis yielded approximately 55% sensitivity and 81% specificity. For PET-
scans, the corresponding values were a little better, 77% sensitivity and 86% specificity. To 
limit the number of futile surgeries, which often occur as result of underestimated staging, ad-
vanced staging must be performed through histological evaluation of biopsies. (Silvestri, et al., 
2013) 
  
Table 1: Staging of lung carcinoma in relation to TNM status 
 
 
 N0 N1 N2 N3 
T1 IA IIB IIIA IIIB 
T2a IB IIB IIIA IIIB 
T2b IIA IIB IIIA IIIB 
T3 IIB IIIA IIIB IIIC 
T4 IIIA IIIA IIIB IIIC 
M1a IVA IVA IVA IVA 
M1b IVA IVA IVA IVA 







Widespread analyses have defined NSCLC as a set of distinct diseases that carry substantial 
heterogeneity in terms of cellular and genetic property. Introduction of advanced methods for 
gathering genomic information, such as next-generation sequencing, have enabled a deeper 
look into the genomic alterations that precede NSCLC and have subsequently revealed novel 
therapeutic targets. Advanced genetic methods have also revealed the complexity of these tu-
mors as they possess alterations not only in traditional protein kinases but also epigenetic mod-
ifiers, transcription factors, splicing factors and genes involved in modifying immunological 
response to tumors. The two main forms of NSCLC, LUSC and LUAD, have different tenden-
cies to their pathophysiology that are reflected in their genetic and histological appearance. 
(Chen, et al., 2014) 
 
LUSC generally emerges from the proximal airways and its histological differentiation into 
squamous cell resemblances pseudostratified columnar epithelium that is lining nearby anatom-
ical sites, namely the upper airways and tracheal area. Genetic disparities are evident, but some 
are more modest than others as many genetic alterations share a close frequency in both sub-
types, few examples of this are TP53 and receptor tyrosine kinase gene encoding neurofibromin 
1. Genes that have shown mutations and preference towards LUSC include fibroblast growth 
factor receptor 1 (FGFR1), FGFR2, FGFR3, cluster of differentiation 167b, phosphoinositide 
3-kinase and phosphatase and tensin homolog. However, the number of genetic alterations spe-
cific to LUSC is smaller compared to LUAD. (Chen, et al., 2014) 
 
LUAD typically arises in the more distal airways and the histology is often glandular. Genetical 
alterations that have greater recurrence in LUAD include KRAS, EGFR, but also fusion onco-
genes such as ALK and the ROS1 receptor tyrosine kinase. The incidence of mutations is 5-6 
times smaller in the never-smoking population. (Chen, et al., 2014) 
 
Interaction with the immediate microenvironment surrounding the tumor is vital in the tumor-
igenesis of all cancers. The relationship between these two differ by tumor type, as sometimes 
adapting the microenvironment helps stabilize the growth, and in others stands to block further 
growth or even favor tumor degradation. Lung cancers typically aim to promote local angio-
genic action as increasing flow of nutrients is essential to their growth. Platelet-derived growth 
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factor and vascular endothelial growth factor (VEGF) are some of the signal proteins secreted 
by tumors to induce angiogenesis. Attraction and increased traffic of white blood cells of both 
myeloid and lymphoid lineages benefits the tumor. The mechanism for this effect remains 
vague, but it is believed leucocytes ability to degrade the matrix of microenvironment potenti-
ates tumor progression. Leucocytes also appear to promote tumor cell proliferation, metastases, 
and angiogenesis. Tumors alone can evade the natural immunological processes by displaying 
immune receptor programmed cell death protein 1 (PD-1). (Chen, et al., 2014) 
 
1.5 Prognosis 
In contrast with the positive progress of other cancers, the outlook for lung cancer remains 
relatively modest. The age standardized 5-year net survival percentage remains generally lower 
than 20% depending on geographical location. This is largely attributed to tumors being diag-
nosed at a later stage, which is more often a predictor of bad outcome. (Allemani, et al., 2015) 
 
The United States National Cancer Institute Surveillance, Epidemiology, and End Results Pro-
gram (SEER) has tracked nations cancer statistics regarding NSCLC from 1975 to 2017. 
General prognosis for men and women has always held a gap of 6-10% favoring women. Racial 
discrepancy in the US favors whites over blacks, and the current 3-6% gap appears to be wid-
ening every year. However, improvements in diagnostics and treatment have had some positive 
impact as overall 5-year relative survival has climbed from around 16% to around 26% in the 
past 40 years. (Noone, et al., 2018) 
 
Greatest impact for prognosis by far comes from the stage at which the cancer is diagnosed. 
Females tend to have their cancers diagnosed earlier than men. Discovering the tumor at a lo-
calized stage offers over 60% chance of 5-year relative survival, but that number drops signif-
icantly if the tumor has metastasized, yielding only around 7% survival rate. Data from SEER 
reveals mismatch between late diagnosis and 5-year relative survival (Table 2), which drags the 






Young people (age <40) have been shown to have more NSCLC that carry genomic alterations 
that are targets for oncogenic treatments, but prognosis in these cases is as bad as with old 
patients (aged 70+), interestingly, the age groups in between that carry these treatable oncogenic 
alterations have better survival rate. The reason for this remains unclear, but one hypothesis 
suggests that NSCLC harboring certain mutations in younger people might be more aggressive 
than the ones present in older populations. Younger age in general is associated with consider-
ably better prognosis. People younger than 45 have 5-year relative survival of 38.7%, while for 
people older than 75 that number is 20.8%. Partial explanation might be the accumulation of 
poorly treatable LUSC in older people, as the effects of smoking begin to weigh. (Sacher, et al., 
2016, Noone, et al., 2018) 
 
Survivors of NSCLC are suggested to have an intense follow-up period involving general ex-
amination every 3-6 months and a low-dose axial CT scan every 6 months for 1-2 years, fol-
lowed by annual checks and CT-scans for years 3-5+ afterwards. (Shapiro, 2018) 
  
Table 2: Stage distribution (%) versus 5-year Relative Survival (%) 2008-2014 by 
Stage at Diagnosis 
 
Stage at Diagnosis Both 
Sexes 
Males Females 
Localized 19 vs 60.1 17 vs 53.7 22 vs 65.6 
Regional 24 vs 33.4 24 vs 29 23 vs 38.4 
Distant 55 vs 5.5 57 vs 4.5 53 vs 6.7 






2 Current Treatments 
2.1 Surgery 
Surgery is the primary treatment for patients with NSCLC clinically staged I, II and some se-
lected IIIA disease. The challenge of surgery lays with balancing the adequate resection of the 
tumor, while preserving the functionality of the remaining lung tissue (Zappa & Mousa, 2016). 
The standard procedure for surgical candidates is lobectomy by video-assisted thoracoscopic 
surgery (VATS) (Gridelli, et al., 2015). 
 
Adjuvant therapy is commonly used to prolong survival and reduce the risk of relapse. Options 
for adjuvant therapy include radiation therapy, chemotherapy, and targeted therapy. Stages IIA, 
IIB and IIIA are usually treated with postoperative chemotherapy to prolong survival. (Zappa 
& Mousa, 2016) One meta-analysis based on 34 trials comparing surgery plus chemotherapy 
versus surgery alone showed increased survival of 4% at 5 years (95% confidence interval (CI) 
3-6). Second meta-analysis based on 13 trials comparing surgery plus radiotherapy and chem-
otherapy versus surgery plus radiotherapy also showed estimated 4% increase in 5-year survival 
(95% CI 1-8), reinforcing the beneficial effect of adjuvant chemotherapy. (Burdett, et al., 2015) 
 
Several techniques have been developed to achieve resection, each suited better for different 
kinds of situation. Lobectomy is generally regarded the primary surgical procedure for lung 
cancer. The procedure includes the resection of a single lobe and adjacent lymph nodes. As 
compared to more radical resections, lobectomy has better potential for preserving pulmonary 
function. Mortality for lobectomy is 2-4%. A variation of this technique is the sleeve lobectomy, 
in which a part of the common airway is removed along with the resection of the lobe.  Airway 
reconstruction, accomplished either by using intercostal muscles or by pleural wrapping of the 
anastomosis, concludes the operation. As a more complicated variant to traditional method, the 
sleeve lobectomy carries slightly higher post-operative burden, mortality and morbidity range 
from 2% to 11%. Sleeve lobectomy is used as an alternative to pneumectomy in a subset of 
patients with bronchogenic carcinoma. (Rotman, et al., 2015) 
 
Pneumectomy removes an entire lung along with its lymph nodes. This radical procedure might 
be indicated when larger areas of the lung or bronchi are affected. Modifications of this surgery 
include intrapleural pneumectomy, in which the visceral pleura is also removed, and extrapleu-
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ral pneumectomy, which involves resection of the lung, pleurae, and even the proximal peri-
cardium and hemidiaphragm. Mortality for pneumectomy is 6-8%. (Rotman, et al., 2015) 
 
In wedge resection, the tumor and some margin of healthy proximal parenchyma is removed. 
The resected area is small, and non-anatomical boundaries are used. Small tumors, metastatic 
lesions, lung biopsies and early-stage cancers in the elderly are included in the list of indications 
for this procedure. Being minimally invasive in nature, this technique is associated with lesser 
rates of complications. (Rotman, et al., 2015) The overall 5-year survival rate hovers near the 
outcomes of other surgical techniques, but radically drops to being inferior if indication is con-
servative surgery for patient with many co-morbidities. Wedge resection should only be per-
formed on carefully selected patients with adequate indication. (Nakamura, et al., 2011) 
 
Wedge resection is often performed utilizing VATS or robot-assisted thoracoscopic surgery. 
Meta-analysis of 21 studies concluded that VATS has no statistical difference to open lobec-
tomy in terms of post-operative complications or locoregional tumor recurrence, but systemic 
recurrence rate was lower (risk ratio (RR)=0.57; 95% CI, 0.34-0.95; p=0.03) and 5-year sur-
vival rate was improved (RR=0.72; 95% CI 0.45-0.97; p=0.04). Some of these studies were not 
randomized. Patient selection was also biased, possibly influencing the outcomes. (Yan, et al., 
2009) 
 
An alternative to lobectomy, segmentectomy can be performed to a selected group of patients. 
This method resects larger margins and more lymph nodes compared to wedge resection, but 
spares tissue in comparison to traditional lobectomy. As in wedge resection, VATS can be uti-
lized in this method to yield better outcomes and shorter recovery times compared to thoracot-
omy. (Rotman, et al., 2015) 
 
The topic of lymph node dissection has not been settled in literature and while sometimes lymph 
nodal evaluation is done by visual inspection of the unopened mediastinum, others opt on sur-
gical approach. Two methods of surgical intervention are used to evaluate lymph node involve-
ment in lung cancer. Sampling means the removal of one or more lymph nodes, which are 
selected based on pre-operative or intra-operative findings. Systematic or full nodal dissection 
means the removal of all lymph nodes including the neighboring mediastinal tissue within an-




The European Society of Thoracic Surgeons recommended in their guidelines (2006) that 
achieving total resection requires systematic lymph node dissection. For a peripheral squamous 
T1-tumor, selective nodal dissection is acceptable, as the lymphatic drainage in the area creates 
low-risk environment for unforeseen N2 disease. (Lardinois, et al., 2006) 
 
One meta-analysis based on 3 studies also concluded that in patients with cancer stages I to IIIa, 
mediastinal lymph node dissection appeared to improve survival rates compared with medias-
tinal lymph node sampling (hazard ratio (HR) 0.63, 95% CI 0.51-0.78). (Manser, et al., 2005) 
 
Advances in surgery have reduced the invasiveness, making the surgery less prone to compli-
cations. Japanese Lung Cancer Registry study data shows that the death rate within 30 days 
after resection has decreased from 1.4% in 1994 to 0.4% in 2004. (Sawabata, et al., 2011) 
 
The US National Cancer Institute have constituted the Common Terminology Criteria for Ad-
verse Effects. The criteria range from grade 1 to grade 5 which, in ascending order, are mild, 
moderate, severe, life-threatening or death. (NCI, 2019) 
 
Post-surgical complications are divided into two groups, immediate- and late complications. 
The diagnosis is heavily dependent on chest x-rays and computed topography, as many com-
plications have a distinct radiographic pattern. Immediate complications take place during the 
days 0-30 postoperatively. The most common of these include atelectasis of the lung, pneumo-
nia, empyema, and prolonged air leak. Some of the rarer complications include lung torsion, 
oedema, and cardiac herniation. Pneumonia is the leading cause of postoperative mortality, it 
affects 2-22% of the patients and has mortality rate of up to 25%. Other serious complications 
are bronchopleural fistula, pulmonary edema (50-100% mortality) and acute respiratory syn-
drome (80% mortality). Late complications appear after the 30-day mark postoperatively. These 
include bronchial anastomotic stenosis, late bronchopleural fistula, late onset empyema, esoph-
agopleural fistula and postpneumectomy syndrome. (Rotman, et al., 2015) 
 
Tumor recurrence can be regarded as a form of long-term complication. Locoregional tumor 
recurrence presents as regional tumor in mediastinal wall, parietal pleura, surgical margins or 
as metastases in the mediastinal lymph nodes. Rate of recurrence in a 5-year period is 20-30% 




Pulmonary impairment due to pre-existing illness such as chronic obstructive pulmonary dis-
ease (COPD) can dramatically alter the operability of a patient. Almost 37% of patients that 
have been diagnosed with lung cancer and are suitable for anatomical resection are deemed 
inoperable due to severe pulmonary function impairment. For these patients, the rates for sur-
gical morbidity and mortality are 83% and 33% respectively. Rehabilitation before surgery with 
physical training has been hypothesized to improve survivability, as it is a known to reduce 
post-operative morbidity and mortality of colorectal, heart and spinal surgery. The oncological 
timing for lung cancer, however, does not allow for long endurance training periods and shorter 
periods of more intensive training has been proposed. No clear statistical evidence has yet been 
reported, but COPD patients probably benefit from preoperative rehabilitation training. 
(Sanchez-Lorente, et al., 2018) 
 
2.2 Radiotherapy 
Radiotherapy can be applied externally or internally. Internal radiotherapy is preferred, if radi-
ation source can be placed near the tumor and is therefore mainly used for treating cancers in 
gynecological areas, anorectal area, or the eyes. External radiotherapy is used for most cancers. 
It utilizes distant source, such as x-ray machines, proton- or neutron beam machines to deliver 
radiation. The unit for dose is Gray (Gy), which is defined as one joule of radiation energy per 
kilogram of matter. The two most common methods for external radiation are external beam 
radiotherapy (ERBT) and stereotactic body radiation therapy (SBRT). (Noone, et al., 2018) 
 
Radiotherapy can be used in all stages of lung cancer and while sometimes used for palliative 
care, extensive and ongoing advancement of technologies and research have enabled the use of 
radiotherapy increasingly as curative option, particularly when combined with systemic therapy 
or surgery. (Brown, et al., 2019) 
 
Surgery persists as the primary treatment for early stage (stage I/II) NSCLC. However, some-
times pre-existing conditions (e.g., COPD or severe cardiovascular disease) cause the patient 
to be classified as “medically inoperable”. Patients who refuse surgery are also classified as 
such, and radiotherapy is subsequently offered as an alternative. (Abel, et al., 2019) SBRT has 
become a viable alternative to surgery largely owing to its efficacy, convenience, and accepta-
ble toxicity profile (Kann, et al., 2019). A large study using univariable and multivariable anal-
yses comprising of 15,110 subjects that had early-stage NSCLC found the median OS to be 44 
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months for LUAD and 33 months for LUSC (p<0.0001). OS at predetermined time intervals 
were 85% versus 83% at 1 year, 58% versus 43% at 3 years and 36% versus 24% at five years 
for patients diagnosed with LUAD and LUSC, respectively (p<0.0001). Improved survival was 
associated with female sex, African American race, T1 lesions, age <75 and LUAD histology. 
(Abel, et al., 2019) Patient selection inherently makes the comparison between surgery and 
radiotherapy difficult, as radiotherapy is often only considered after the patient is considered 
in-operable. Analysis comparing the outcomes of 143 patients treated with surgery against 197 
patients treated with SBRT found  no difference in OS (HR 1.07; 95% CI 0.74-1.54; p=0.73), 
when prognostic covariables were adjusted for. (van den Berg, et al., 2015) One review showed 
similar 2-year OS after SBRT (70%, 95% CI; 67-72%) and surgery (68%, 95% CI; 66-70) for 
stage I patients (Soldà, et al., 2013). 
 
The treatment for inoperable locally advanced (stage III) NSCLC has changed very little during 
the past 30 years. The standard is concurred chemoradiotherapy and although high dose of ra-
diation delivered to the tumor is associated with higher tumor resolution, this effect has not 
been observed when applying dose escalation to the standard treatment. (Brown, et al., 2019) 
On the contrary, one randomized Phase III trial (RTOG 0617) with subjects having stage IIIA/B 
disease compared 60Gy and 74Gy radiotherapy (with or without cetuximab), the median sur-
vival for patients with higher dose was 20.3 months versus 28.7 months for the standard dose. 
This gap was partly explained by the increased toxicity and complications related with higher 
doses. (Bradley, et al., 2015) Median survival for stage III NSCLC treated with radiotherapy 
has improved significantly over the last 20 years. Better staging and advanced preoperative 
imaging deserve some credit, but the increased survival is mostly attributed to the addition of 
immunotherapy. (Brown, et al., 2019) One year of durvalumab following radiotherapy in-
creased the 2-year OS (66.3% with durvalumab versus 55.6 with placebo). Progression-free 
survival (PFS) was also increased (median, 28.3 months versus 16.2 months). (Antonia, et al., 
2018) Concurrent chemoradiotherapy is more effective treatment to radiotherapy alone as will 
be discussed later (O'Rourke, et al., 2010). 
 
Palliative radiotherapy is used in metastatic (stage IV) NSCLC. The objective is to decrease 
symptoms such as pain, cough, and hemoptysis. New interest in treating oligometastatic 
NSCLC has surfaced, as several studies have demonstrated radiotherapy to have positive effect 
on the OS, with patients granted several months of median survival as opposed to standard 
maintenance therapy. However, these studies are not sufficient to draw final conclusions and 
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phase III evidence is still required. Many studies are currently examining the use of radiother-
apy in metastatic NSCLC. (Brown, et al., 2019) 
 
ERBT involves delivering relatively small doses of radiation (1.8-2Gy per fraction) to the tumor 
via two-dimensional beams using a linear accelerator. Planning of the procedure does not in-
volve 3D-imaging by CT, as it can instead be accomplished with diagnostic X-ray machine and 
the treatment is guided based on these images. Detailed anatomy of the tumor is lacking and 
therefore dose absorbed into the healthy tissue is greater than in more advanced techniques. 
Outcomes are disappointing and SBRT has replaces EBRT as the primary radiation therapy. 
(Parashar, et al., 2013) 
 
SBRT utilizes multiple small, accurate and highly focused external beams of radiation to con-
duct large doses (e.g., 20Gy per fraction) on the tumor. Treatment is performed during several 
sessions over a few weeks. The method is noninvasive and guided by advanced imaging, which 
allows well-defined small tumors to be treated. Indications for the use of SBRT includes tumors 
less than 5 cm in diameter in which lymph nodes are negative, tumors should also have a dis-
tance minimum of 2 cm from the tracheobronchial tree, as proximity to central areas increases 
the risk of complications. SBRT can be used extracranially. (Timmerman, et al., 2010) Multiple 
techniques can be used to deliver SBRT treatments, such as using a conventional linear accel-
erator in fixed field mode or dynamically with intensity modulated fixed field mode. (Parashar, 
et al., 2013, van den Berg, et al., 2015)  
 
SBRT is associated with excellent local disease control. Challenges for this method are regional 
and distant failures, which often lead to increased morbidity and mortality. Recurrence occurs 
in 20-30% of patients. There is also a significant risk of clinically occult nodal metastases, with 
increased risk related to tumor size. The primary pattern of failure is regional-distant, but the 
risk can be reduced by combining SBRT with systemic-therapy. Local recurrence is signifi-
cantly higher in LUSC as opposed to LUAD histology, partly explaining the difference in sur-
vival. (Kann, et al., 2019) Locoregional failure is also more prevalent in SBRT than in surgery 
(van den Berg, et al., 2015). 
 
Technological advancements have allowed the tumor mass to be better distinguished from the 
healthy tissue and subsequently higher doses of radiation can be used to deliver better results. 
Still, normal tissue cannot be completely separated from the radiated area, which is why the 
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topic of complications stays relevant and must always be considered before the treatment. Post-
radiation therapy complications arise locally as healthy tissues are damaged. Adjacent struc-
tures include the healthy lung, pleura, heart, great vessels, thymus, lymph nodes, esophagus, 
liver, breast, and bones.  Complications (Table 3) are divided into early- and late complications. 
Early complications are manifested in the following weeks or months after the radiotherapy. 
Late complications typically manifest after several months or even years. (Baker, et al., 2016, 
Benveniste, et al., 2019) 
 
Given the low prognosis for untreated NSCLC, there are no absolute contraindications for ra-
diotherapy. Active interstitial lung disease may be an important risk factor for severe toxicity 
and is considered a relative contraindication. (Shultz, et al., 2015) Toxicity and the risk for 
complications is also increased for central tumors, which are located within two centimeters in 
all directions of any vital anatomy in the mediastinum (Baker, et al., 2016). 
 




Early complications(s) Late complication(s) 
Lungs Infection, organizing 
pneumonia 
Tumor recurrence 
Pleura Pleural effusion … 
Heart Pericardial effusion Coronary artery disease, valvular disease, 
cardiomyopathy, chronic pericarditis 
Great 
vessels 
Vascular stenosis Vascular wall calcifications, vascular 
occlusion, pseudoaneurysm 
Thymus Simple cysts … 
Lymph 
nodes 
… Calcified lymph nodes, fibrotic mass 
Esophagus Ulceration, esophageal 
dysmotility, perforation, 
fistula 
Stricture, ulceration, fistula 
Liver Focal hepatitis Atrophic liver changes 
Breast Diffuse skin thickening Fat necrosis, dystrophic calcification, 
skin retraction 
Bones Edema and osteopenia Pathologic fractures, osteochondromas 
and osteoradionecrosis. 
Malignancy Local or distal recurrence Radiation-induced thoracic malignancies 






At 5 years endpoint, patients with early-stage NSCLC treated with SBRT have a risk for local 
or distant recurrence of 9-20% and 20%, respectively. Locally advanced NSCLC have local 
and distant recurrence of 30-40% and 40-50%, respectively. (Baker, et al., 2016) 
 
2.3 Chemotherapy 
Chemotherapy has a broad spectrum of indications in the treatment of NSCLC. Chemotherapy 
is used as an adjuvant therapy in stages II/IIIA NSCLC in combination with surgical resection 
to enhance survival, for chemotherapy can address the possible dissemination of tumor cells 
and distant spread, something the local intervention fails to do. Neoadjuvant chemotherapy has 
the rationale of attenuating the central tumor prior to surgery, but studies have shown it to have 
no benefits and is therefore not recommended. For the unresectable stage III NSCLC, concur-
rent chemoradiation therapy is preferred, but the 5-year prognosis remains poor, as only 15% 
of patients are alive. Stage IV NSCLC requires systemic treatment and platinum doublet chem-
otherapy has traditionally been the standard. However, the advent of immunotherapy has 
changed the treatment of metastatic NSCLC as will be discussed later. (Duma, et al., 2019) 
 
Lung Adjuvant Cisplatin Evaluation (LACE) comprised analysis of five large trials (4584 pa-
tients) in which patients had underwent complete resection and had received adjuvant cisplatin-
based chemotherapy. Several drugs used to complement the platinum base included etoposide, 
vinorelbine and vina-alkaloid. However, no statistically relevant difference between their effi-
cacy was observed. The results showed a 5-year absolute benefit of 5.4% (HR of death was 
0.89, 95% CL, 0.82 to 0.96, p=0.005). For stage IA NSCLC chemotherapy showed to increase 
the risk of death (HR of 1.40, 95% CI 0.95-2.06). Stage IB remains controversial and might be 
beneficial to a high-risk individual. LACE study showed only mildly improved benefit for IB 
disease (HR 0.93, 95% 0.78-1.10). Stage II demonstrated a clear benefit (HR 0.83, 95% CI, 
0.73-0.95) as did stage III NSCLC (HR 0.83, 95% CI, 0.72-0.94). (Pignon, et al., 2008) 
 
Adjuvant chemotherapy is also beneficial in patients (stage II-IIIA NSCLC) treated with sur-
gery or surgery plus radiotherapy as discussed earlier. The addition of chemotherapy corre-
sponded to a 4 percent increase in OS at 5 years (33 versus 29 percent). (Burdett, et al., 2015) 
 
Concurrent chemoradiotherapy is the standard for unresectable stage III NSCLC. The optimal 
choice of chemo agent remains unclear. A multicenter randomized phase III trial found the 
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combination of etoposide/cisplatin (EP) to be superior against carboplatin/paclitaxel (PC) (3-
year estimated difference in OS was 15.0%, p=0.024), median survivals were 23.3 months and 
20.7 months, respectively. Pneumonitis (grade 2 or higher) was more common with PC and 
esophagitis (grade 3 or higher) was more common with EP. (Liang, et al., 2017) 
 
For decades, the treatment of advanced NSCLC has heavily relied on platinum-based cytotoxic 
chemotherapy. Although new agents and novel combinations have been tested in many trials, 
non-platinum combinations have not shown superior results. (Lwin, et al., 2013) Whilst poor 
outcome for advanced NSCLC is inevitable, chemotherapy improves OS in all patients when 
compared to supportive care. Meta-analysis and systematic review of 16 randomized controlled 
trials (RCTs) concluded that chemotherapy produced significant benefit (HR, 0.77; 95% CI, 
0.71-0.83; p<0.0001), which translates to absolute improvement in survival of 9% at 12 months. 
This analysis concluded that the drug of choice, or whether single agents or combination was 
used, had no effect. (NSCLC Meta-Analyses Collaborative Group, 2008) 
 
The discovery of treatable oncogenic-driver pathways has transformed the research of advanced 
NSCLC into a swiftly evolving platform, as new treatments are being implemented for selected 
patients. Most patients, however, do not harbor actionable driver mutations and chemotherapy 
is the primary treatment for them. For all categories of NSCLC without EGFR mutation or ALK 
fusion, a platinum-based doublet therapy is favored. Patients with actionable driver mutations 
who are initially treated with targeted medicine, eventually develop resistance and subsequent 
chemotherapy is indicated. Targeted therapy with concurrent chemotherapy might be beneficial 
and studies on this subject are ongoing. Prior research did not indicate increased survival when 
concurrent chemotherapy was combined with EGFR-inhibitors. (Lwin, et al., 2013) 
 
Chemotherapeutic substances have distinct dose-limiting side effects, some of which can be 
treated with other medicines and others not. Chemotherapeutic agents can cause both central 
and peripheral neurotoxicity. Transient bone marrow suppression, leading to neutropenia, ane-
mia, and thrombocytopenia, is common side-effect of most chemotherapeutic drugs. 
Neutropenia is a significant rate-limiting factor with many drugs, including docetaxel and 
paclitaxel. Cardiac toxicity leading to myocyte death and subsequent heart problems are com-
mon with anthracyclines. Nephrotoxicity can lead to hemolytic-uremic syndrome. Ocular tox-
icity ranging from mild conjunctivitis to permanent blindness are reported with a plethora of 
agents. Ototoxicity is commonly attributed to cisplatin and carboplatin. Other complications 
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include pulmonary reactions, mucositis, nausea and vomiting, constipation, gastrointestinal 
hemorrhage, pancreatitis, hepatotoxicity, hemorrhagic cystitis, and cutaneous reactions. 
(Livshits, et al., 2014) 
 
Dose-limiting aspect of cisplatin is nephrotoxicity, other side-effects include cumulative pe-
ripheral sensory neuropathy, ototoxicity, nausea, and vomiting. Many tumors have intrinsic re-
sistance to this drug, while other tumors gradually build tolerance as the treatment progresses. 
(Dilruba & Kalayda, 2016) 
 
Carboplatin has a similar toxicity profile to cisplatin, but the overall toxicity is markedly lower. 
High-dose chemotherapy can therefore be performed with this agent. Myelosuppression is the 
dose-limiting side-effect of carboplatin, but modern hematopoietic colony-stimulating actors 
can be used to counter this. Dose-limiting side effect for third generation platinum-based drug 
oxaliplatin is neurotoxicity. (Dilruba & Kalayda, 2016) 
 
2.4 Immunotherapy 
Immune checkpoint inhibitors (ICIs) have drastically improved the treatment of late-stage 
NSCLC. These agents function by blocking inhibitory pathways that tumors can exploit to 
physiologically evade immune system. In the case of NSCLC, the ICIs of interest are PD-1, 
PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The mechanisms of these 
molecules heavily revolve around T cells, which in turn modulate the natural immune response 
to foreign entities, including cancers, in the human body. (Proto, et al., 2019) Although targeted 
therapies are under intensive development, majority of the patients have no targetable altera-
tions in their tumor genetical make up and it is these patients that have gained the benefits of 
immunotherapy. Immunotherapy increases OS and quality of life in advanced NSCLC and is 
routinely used. (Hanna, et al., 2020) 
 
The tumor proportion score (TPS) describes the relative amount of tumor that expresses PD-
L1, a transmembrane protein that suppresses immune response against the cell. Higher TPS 
predicts better response when anti-PD-1 and anti-PD-L1 therapies are used. The American So-
ciety of Clinical Oncology and Ontario Health NSCLC Expert Panel have made recommenda-
tions for treating stage IV NSCLC patients without driver mutations. The recommendations 




Patients with TPS ≥50% clearly benefit from immunotherapy. For patients with non-LUSC and 
TPS ≥50%, single agent pembrolizumab is recommended. (Hanna, et al., 2020) KEYNOTE-
042 trial included 1,274 randomly assigned participants, 47% of which had a TPS ≥ 50%. Single 
agent pembrolizumab plus chemotherapy doublet (treatment arm) and chemotherapy doublet 
(control arm) were compared. When comparing all patients, the addition of pembrolizumab 
significantly increased OS (HR 0.69, 95% CI, 0.56-0.85; p=0.0003). Treatment arm saw 2-year 
OS improve from 30% to 50%. Adverse effect for patients with TPS ≥ 1% were less prominent 
in the treatment arm. KEYNOTE-042 trial did not find statistically significantly greater OS 
with treatment arm (HR, 0.82; 95% CI, 0.63-1.07; p=NS), however treatment arm was numer-
ically favored. Favorable toxicity profile also makes the treatment less demanding for the pa-
tient. (Mok, et al., 2019) 
 
KEYNOTE-189 compared pembrolizumab plus platinum doublet (treatment arm) with placebo 
plus platinum doublet (control arm) in patients with non-LUSC NSCLC. The treatment arm had 
greater OS (HR, 0.42; 95% CI, 0.26-0.68). While these results inevitably question the recom-
mendations based on KEYNOTE-042 trial, the combination therapy is more toxic and finan-
cially demanding, which must affect decision making. (Mok, et al., 2019, Gadgeel, et al., 2020) 
Optional therapy with pembrolizumab plus platinum-doublet is a viable alternative for patients 
with non-LUSC TPS ≥50%.  Trials comparing the effectiveness of pembrolizumab monother-
apy versus pembrolizumab plus platinum doublet are lacking. (Hanna, et al., 2020) 
 
For patients with LUSC and TPS ≥50%, single agent pembrolizumab is recommended (Hanna, 
et al., 2020). KEYNOTE-042 study concluded that patients with LUSC and TPS ≥ 50% benefit 
from single-agent pembrolizumab (HR 0.53, 95% CI, 0.38-0.75) (Mok, et al., 2019). 
KEYNOTE-407 study found the combination of pembrolizumab plus platinum doublet to have 
1-year survival of 63.4% versus 51% for those receiving placebo plus platinum doublet HR for 
OS was 0.64 (95% CI, 0.37-1.10), these finding however, were not statistically relevant. (Paz-
Ares, et al., 2018) 
 
Patients with TPS negative (0%) or low positive (1%-49%) also seem to benefit from immuno-
therapy. For patients with non-LUSC and TPS negative or low positive, pembrolizumab plus 
platinum doublet (carboplatin/pemetrexed) is recommended. (Hanna, et al., 2020) KEYNOTE-
189 showed clear survival benefit for pembrolizumab plus platinum doublet versus placebo 
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plus platinum doublet in patients with TPS 1% to 49%. Twelve-month survival rate was 71.5% 
in the treatment arm and 50.9% in the control arm (HR, 0.55; 95% CI, 0.34-0.90). Patients with 
TPS <1% also benefitted from treatment (HR, 0.59; 95% CI, 0.38-0.92). (Gadgeel, et al., 2020) 
Optional treatment for non-LUSC NSCLC with TPS <50% is the combination of atezolizumab 
plus bevacizumab plus platinum doublet. This combination is particularly promising for pa-
tients with EGFR mutation or ALK rearrangements, that have experienced disease progression 
after tyrosine kinase inhibitor (TKI) therapy. (Proto, et al., 2019) 
 
For patients with LUSC and TPS negative (0%) or low positive (1%-49%), pembrolizumab 
plus platinum doublet (carboplatin/(nab-)paclitaxel) or chemotherapy alone is recommended. 
(Hanna, et al., 2020) The KEYNOTE-407 study compared pembrolizumab plus platinum dou-
blet versus chemotherapy alone. The subgroup with TPS <1% had greater OS than control arm 
(HR 0.61, 95% CI 0.38-0.98) and as did the subgroup with TPS 1%-49% (HR 0.57, 95% CI 
0.36-0.90). (Mok, et al., 2019) 
 
Ipilimumab, a monoclonal antibody targeting the CTLA-4 protein is another novel option for 
the treatment of NSCLC. It offers a viable alternative, not on its own but rather in the form of 
combined immunotherapy. Ipilimumab combined with nivolumab (PD-1 antibody) was tested 
in a phase III trial against chemotherapy or several combined therapies. In patients with 
TPS>1%, ipilimumab plus nivolumab proved superior against chemotherapy as results showed 
median duration of OS of 17.1 months (95% CI, 15.0-20.1) versus 14.9 months (95% CI 12.7-
16.7), 2-year survival of 40.0% versus 32.8%, and median duration of response of 23.2 months 
versus 6.2 months, respectively. Ipilimumab plus nivolumab against nivolumab monotherapy 
alone showed 2-year OS of 40% versus 36.2% and median duration of response of 23.2 months 
(95% CI 15.2-32.2) versus 15.5 months (95% CI 12.7-23), respectively. The effect of combi-
nation therapy versus nivolumab alone was even more prominent for patients with TPS>50%, 
as 2-year OS was 48.1% versus 41.9% and median duration of response was 31.8 months (95% 
CI, 18.7 to not reached) versus 17.5 months (95% CI 13.5-31.0), respectively. Patients with 
TPS<1% also saw benefit when ipilimumab plus nivolumab was used instead of chemotherapy. 
Median duration of OS was 17.2 months (95% CI, 12.8-22.0) versus 12.2 months (95% CI, 9.2-
14.3), respectively. Ipilimumab plus nivolumab was also superior to nivolumab plus chemo-
therapy, as 2-year OS was 40.4% and 34.7%, while median duration of response was 18 months 
and 8.3 months, respectively. All patients accounted showed less severe reactions to combined 




One meta-analysis compared the effectiveness of ipilimumab plus nivolumab against pembroli-
zumab monotherapy, pembrolizumab plus chemotherapy, nivolumab monotherapy and chem-
otherapy alone. In terms of effectiveness, the combination of ipilimumab plus nivolumab was 
superior to nivolumab monotherapy, pembrolizumab monotherapy and chemotherapy, but in-
ferior to pembrolizumab plus chemotherapy. The combination of ipilimumab plus nivolumab 
however, was generally well tolerated compared to other existing immunotherapeutic treat-
ments. (Ando, et al., 2020) 
 
In stage III NSCLC, the concurrent use of durvalumab (PD-1 antibody) with radiotherapy in-
creased OS as discussed earlier. 4-year follow-up of a phase-3 RCT (PACIFIC) showed the 
addition of durvalumab after concurrent chemoradiotherapy to significantly improve OS, when 
compared against placebo (HR, 0.68; 95% CI, 0.53-0.87, p=0.00251). (Faivre-Finn, et al., 2021) 
 
Adverse effects related to immunotherapy can occur in any organ system and can occur within 
days of initiation to a full year, median onset however, is usually between 2 to 16 weeks. Drugs 
targeting CTLA-4 are more prone to cause adverse effects than PD-1 and PD-L1 inhibitors, but 
the mechanisms underlying this difference are not well known. (Ramos-Casals, et al., 2020) 
Large meta-analysis of 36 phase II/III trials have estimated the general safety of immunother-
apy. Pooled incidence of all adverse effects ranged between 54% to 76% (Xu, et al., 2018).  
The prevalence of endocrinopathies is >10% for CTLA-4 inhibitors and 4-14% for anti-PD-1 
inhibitors. Most common endocrinopathies are hypophysitis, thyroid dysfunction and type 1 
diabetes mellitus. Gastrointestinal adverse effects are rather common. The incidence rates of 
diarrhea for PD-1 inhibitors, CTLA-4 inhibitors and combined therapy are 20%, 35% and 
>40%, respectively. Colitis has a prevalence of 12%, 1% and 14% respectively. The preva-
lence of hepatitis is 1-6%, 1-25% and 17-22%, respectively. Hematological adverse effects, 
most commonly neutropenia, autoimmune hemolytic anemia, immune thrombocytopenia, and 
aplastic anemia are rare (3-4% of total adverse effects). Severe dermatological adverse effects 
(grade 3 or more) occur in 2-10% of patients receiving immunotherapy. Less than 1% of pa-
tients experience cardiac toxicity. However, heart related adverse effects, such as myocarditis, 
can potentially be fatal. (Ramos-Casals, et al., 2020)  
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2.5 Targeted therapy 
Oncogenic driver mutations are identified in 60% of LUADs and in 50% to 80% of LUSCs. 
Targeted therapies against identifiable driver mutations are now routinely used in advanced 
NSCLC. EGFR and ALK are the most common therapeutic targets, while other potential targets 
of interest include gene rearrangements of ROS1 and RET-proto-oncogene, activating mutations 
in BRAF, KRAS and human epidermal growth factor receptor 2 genes and amplification of ty-
rosine-protein kinase Met gene (Zappa & Mousa, 2016, Schroff, et al., 2018). ECOG-1505 trial 
showed no benefit for use of targeted therapies against early-stage NSCLC, but this trial did not 
specifically direct the therapy against patients with targetable mutation (Dahlberg, et al., 2017). 
The ongoing ALCHEMIST screening trial is exploring the use of EGFR-inhibitors and ALK-
inhibitors in their respective mutant populations (NCI, 2021). 
 
EGFR is a cell surface receptor that under dimerization, activates tyrosine kinases, which in 
turn advances several tumorigenic processes, such as cell proliferation, angiogenesis, adhesion, 
motility, and apoptosis. EGFR mutations are more prevalent in adenocarcinomas, women, 
never-smokers, and Asians. (Schroff, et al., 2018) Approximately 15% of LUADs in the USA 
harbored EGFR-mutations. US Food and Drug Administration (FDA) has approved the use of 
four tyrosine kinase inhibitors gefitinib, erlotinib, afatinib and osimertinib for clinical use. 
Several studies have established the role of TKIs in advanced NSCLC with EGFR-mutant pa-
tients. (Naylor, et al., 2016) 
 
Therapeutic potential of EGFR-inhibitors has been investigated in several trials (Table 4). First-
generation gefitinib and erlotinib are reversible competitive adenosine triphosphate inhibitors 
and target only EGFR. A multicenter, open-label phase III RCT (OPTIMAL) showed signifi-
cantly longer PFS of 13.1 months with erlotinib compared to platinum-doublet (Zhou, et al., 
2011). Erlotinib demonstrated potential also in another phase III trial (ENSURE), when both 
PFS and objective response rate (ORR) were considerably better than with platinum doublet 
(Wu, et al., 2015). Another multicenter, open-label, phase III RCT (EURTAC) showed erlotinib 
to have significantly higher PFS (9.7 months) than standard chemotherapy (Rosell, et al., 2012). 
In one phase III RCT (WJTOG-3405), gefitinib also showed similar results compared to plati-
num-based chemotherapy (Yoshioka, et al., 2019). Second-generation TKIs, such as afatinib 
and dacomitinib function as irreversible inhibitors that target EGFR, receptor tyrosine-protein 
kinase erbB-2 and receptor tyrosine-protein kinase erbB-4. The LUX-LUNG-7 and ARCHER-
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1050 trials demonstrated that afatinib and dacomitinib, respectively, have superior PFS com-
pared to gefitinib. (Paz-Ares, et al., 2017, Wu, et al., 2017) 
 
Disease progression inevitably occurs after the initial response, usually after 1-2 years. Up to 
63% of patients treated with TKIs have shown to harbor EGFR T790M mutation upon disease 
progression. After the tumor develops resistance to first generation TKIs, afatinib and 
dacomitinib can be used. In this scenario, however, response rates less than 10% and PFS less 
than 4 months can be achieved. (Jänne, et al., 2015) Subsequently, osimertinib and rociletinib 
have been approved as second line therapy (Naylor, et al., 2016). For patients with T790M-
positive NSCLC who progressed after initial TKI treatment, osimertinib showed ORR of 61% 
and median PFS of 9.6 months (Jänne, et al., 2015). Platinum-based chemotherapy is used for 
patients with T790M-negative NSCLC who progress after initial TKI therapy (Hirsch, et al., 
2017). Third generation TKIs have also been tested against other TKIs in untreated EGFR-
positive NSCLC population. Indeed, both Osimertinib (FLAURA) and dacomitinib (ARCHER-





ALK rearrangements are found in 5% of unselected NSCLC. The prevalence is up to 22% in 
never- or light smokers. Adenocarcinomas harbor nearly 97% of all ALK rearrangements. 
Normal ALK is functional in growing tissue and suppressed when tissue reaches maturity. It 
functions by activating several pathways, including Janus kinase/signal transducers and activa-
tors of transcription, and mitogen-activated protein kinase (MAPK). The echinoderm microtu-
bule-associated protein-like 4 is the most common ALK fusion protein partner. ALK inhibitors 
have been established as the primary therapy against ALK-positive advanced NSCLC. 
(Friedlaender, et al., 2019) In the PROFILE 1014 -trial, first generation TKI crizotinib showed 
superior results when compared to chemotherapy. Results showed ORR 74% versus 45%, PFS 
10.9 months versus 7.0 months, 1-year survival of 84% versus 79% and 4-year survival of 
56.6% versus 49.1%, respectively. (Solomon, et al., 2018) 
 
As with other targeted therapies, disease progression is common. 31% of patients with ALK-
positive NSCLC treated with crizotinib have experienced disease progression at 18 months. 
First generation ALK-TKIs permeate blood brain barrier poorly, and subsequently, 50% of pa-
Table 4: Selected randomized trials with first line TKI therapies 
 
Study Design ORR (%) PFS (months) 
IPASS  Gefitinib vs 
carboplatin plus 
paclitaxel 
72.1 vs 47.3 9.5 vs 6.3 
NEJ002  Gefitinb vs 
carboplatin plus 
paclitaxel 
73.7 vs 30.7 10.8 vs 5.4 
WJTOG-3405  Gefitinib vs cisplatin 
plus docetaxel 
62.1 vs 32.2 9.2 vs 6.3 
EURTAC Erlotinib vs platinum 
doublet 
58 vs 15 9.7 vs 5.2 
ENSURE Erlotinib vs 
cisplatin/gemcitabine 
63 vs 34 11.0 vs 5.5 
OPTIMAL Erlotinib vs 
carboplatin plus 
gemcitabine 
83 vs 36 13.1 vs 4.6 
LUX-Lung-3 Afatinib vs 
cisplatin/pemetrexed 
56 vs 23 11.1 vs 6.9 
LUX-Lung-6 Afatinib vs 
cisplatin/gemcitabine 
67 vs 23 11.0 vs 5.6 
LUX-Lung-7 Afatinib vs gefitinib 72.5 vs 56 11 vs 10.9 
Archer-1050 Dacomitinib vs 
gefitinib 
75 vs 72 10.9 vs 7 
FLAURA Osimertinib vs 
gefitinib or erlotinib 





tients treated with crizotinib have central nervous system progression during the treatment. 
(Friedlaender, et al., 2019) To counter these issues, second generation ALK-TKIs were devel-
oped. Indeed, one phase III RCT (ASCEND-5) demonstrated the use of ceritinib instead of 
platinum-based chemotherapy as second line treatment after disease progression to improve 
PFS (5.4 versus 1.6 months, HR 0.49, 95% CI 0.36-0.67; p<0.0001)). (Shaw, et al., 2017) 
 
Second generation ALK-TKIs have since taken their place as first line treatment in ALK-posi-
tive NSCLC. Alectinib was compared to crizotinib as first line treatment in phase III RCT 
(ALEX). Updated results showed median PFS to be 34.8 months for alectinib and 10.9 months 
for crizotinib. (Camidge, et al., 2019) 
 
Should disease progression occur after treatment with afatinib, third generation TKI lorlatinib 
is recommended, as it remains effective against several common resistance mechanisms. When 
lorlatinib was used to treat ALK-positive NSCLC patients in a treatment naïve cohort, second 
line after crizotinib cohort, second line after second generation TKIs cohort and in patients who 
had received up to three TKIs prior, the ORRs were 90%, 69.5%, 32.1% and 38.7%, respec-
tively. (Friedlaender, et al., 2019) 
 
ROS1 rearrangements are present in 1-2% of NSCLC. Several variants have been discovered 
and they are most prevalent in younger-, female- and light- or never-smoking patients. Crizo-
tinib received approval from the FDA when positive response was recorded in ROS1-positive 
patients mostly pretreated with chemotherapy (72% of patients responded, median PFS 19.2 
months). (Hirsch, et al., 2017) 
 
Mutations in BRAF are another potential driver in NSCLC tumorigenesis that function by stim-
ulating the MAPK pathway. Several genetic alterations are known, with V600E being the most 
prevalent. BRAF alterations are observed in 3-5% of lung cancers, mostly in smokers with 
LUAD. (Hirsch, et al., 2017) Functional studies have shown that concomitant blocking of both 
BRAF and mitogen-activated protein kinase kinase (MEK) leads to significantly increased tu-
mor regression and therefore, both FDA and European Medicines Agency have approved the 
use of BRAF inhibitor dabrafenib plus MEK-inhibitor trametinib for the treatment of BRAF 




Angiogenesis is a core component in several cancers, including NSCLC. Angiogenetic inhibitor 
bevacizumab in combination with chemotherapy is approved in patients with metastatic non-
LUSC NSCLC. (Manzo, et al., 2017) Bevacizumab plus platinum doublet was compared 
against platinum doublet alone in first line setting for advanced NSCLC (E4599). The addition 
of bevacizumab increased both OS (12.3 versus 10.3 months, HR 0.79, p=0.003) and PFS (6.2 
versus 4.5 months, HR 0.66, p<0.001). (Sandler, et al., 2006) Novel antiangiogenic agents 
ramucirumab and nintedanib have also shown promising results. Ramucirumab plus docetaxel 
was compared to docetaxel alone (REVEL). Results showed significant improvement in median 
OS (10.5 months versus 9.1 months, HR 0.86, p=0.023) and PFS (4.5 versus 3.0, HR 0.76, 
p<0.0001). (Garon, et al., 2014) Two phase III RCTs compared nintedanib plus docetaxel to 
docetaxel alone in second line setting in patients with advanced NSCLC. LUME-LUNG 1 
showed that for patients with any histology, nintedanib plus docetaxel produced increased PFS 
than docetaxel alone (3.4 versus 2.7 months, HR 0.79, p=0.0019), OS was not significantly 
different (Reck, et al., 2014). LUME-LUNG-2 showed nintedanib plus docetaxel to increase 
PFS in non-squamous histology NSCLC (4.4 versus 3.6 months, HR 0.83, p=0.04), OS was not 
statistically different. (Hanna, et al., 2016). Ramucirumab/nintedanib plus docetaxel is therefore 
an option for the second line treatment of patients with advanced LUAD NSCLC. (Manzo, et 
al., 2017) 
 
Wide range of adverse effects are associated with targeted therapies (Table 5). However, their 





3 Bacteria-based therapies 
Bacteria-based treatments are an interesting topic of cancer research. Bacteria possess several 
mechanisms that make them unique in this field. Their ability to penetrate tissue, home in on 
tumors, controlled cytotoxicity, ability to transform therapeutic molecules and easy detectabil-
ity are attributes that are unachievable with standard therapies. Salmonella enterica Serovar 
Typhimurium along with some other facultative and obligate anaerobes have shown to accumu-
late in various tumors in mice, subsequently resulting in the inhibition of tumor growth. This 
phenomenon is believed to occur because of immune system activation and/or competition for 
nutrients. (Forbes, 2010) 
 
Bacteria’s intrinsic cytotoxicity combined with their ability to actively secrete virulence pro-
teins and cytotoxic cargo directly into the cell allows for dual approach (Nishikawa, et al., 
2006). 
 
Several challenges remain, for often increased tumor-homing and the ability to colonize tumors 
comes with increased virulence, which could be problematic for immunocompromised late-
stage disease patients. Therefore, controlling bacterial toxicity will be a priority before regula-
Table 5: Possible adverse effects in selected targeted therapies 
 
Class Drugs Adverse effects 
EGFR Erlotinib, afatinib, gefitinib, 
Osimertinib, rociletinib 
Rash, diarrhea, anorexia, 
fatigue, dyspnea, cough, 
nausea, vomiting, interstitial 
lung disease, hepatotoxicity 
ALK Alectinib, ceritinib, 
brigatinib, crizotinib 
Vision disorder, diarrhea, 
edema, hepatotoxicity, 
vomiting, constipation, 
dysgeusia, fatigue, pyrexia, 
pneumonitis 
BRAF Vemurafenib, dabrafenib Other malignancies, 
hypersensitivity reactions, 
dermatologic reaction, QT 
prolongation, 
hepatotoxicity, uveitis 











tory approvals can be achieved. (Forbes, 2010) 
 
Although trials for bacteria-based therapies are beginning to emerge, available treatments have 
remained scarce. Moxetumomab pasudotox is a recombinant immunotoxin. In this drug, a frag-
ment of anti-CD22 monoclonal antibody is fused to a fragment of a Pseudomonas exotoxin. 
The FDA has approved the use of this drug for patients with relapsing or refractory hairy cell 
leukemia. (Falini & Tiacci, 2019) 
 
One phase I/II trial utilizes immunotherapy based on attenuated Listeria monocytogenes bioen-
gineered to elicit immune response against antigens commonly found in NSCLC. The strain 
(A503) is used in combination with pembrolizumab as their mechanisms complement each 
other. Toxicity profile of A503 was deemed safe for patients with metastatic LUSC or non-
LUSC NSCLC. A503 alone induced immune response and further results are expected in 2023. 
(Ramalingam, et al., 2020)  
 
Another phase I trial tested Listeria monocytogenes-based vaccines and their ability to stimulate 
both innate and adaptive immunity. Results showed generally safe toxicity profile, indicating 
the possibility for further trials. Patients with mesothelioma, lung, pancreatic and ovarian can-
cers as well as patients with liver metastases were evaluated. Immune activation, measured by 
serum cytokine levels and natural-killer cell activation, was observed. (Le, et al., 2012) 
 
4 Discussion 
For the most part, cancer remains a disease of the elderly. Modern therapeutic successes on 
cardiovascular diseases, infections and other historically demanding diseases have left the role 
of cancer be ever more central in the future. The dual effect of decreasing smoking and ageing 
population is poised to increase the relative percentage of non-LUSC NSCLC, thus providing 
a fruitful ground to develop novel treatments, as mutational burden and 5-year prognosis are 
generally better. Early diagnosis still proves to be challenging, as prognosis is directly bound 
to cancer stage at the time of diagnosis. but the inevitable shift towards more advanced therapies 
will keep progressing, as trials are performed to expand the use of targeted therapies and im-
munotherapies into earlier stages. Genetic profiling of the tumor will remain the key aspect in 
their use. Surgery, radiotherapy, and chemotherapy will remain the backbone of lung cancer 




Resurfaced interest in bacteria-based therapies will be an interesting approach, as the natural 
capabilities of bacteria and their limitless potential for enhancements can be widely exploited 
to serve therapeutic effort through multiple mechanisms, either as a monotherapy or by com-
plimenting another treatment (Sedighi, et al., 2019).   
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Appendix 1 – Abbreviations 
ALK Anaplastic lymphoma kinase 
BRAF v-Raf murine sarcoma viral oncogene homo-
log B 
CI Confidence interval 
COPD Chronic obstructive pulmonary disease 
CT Computed tomography 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
EGFR Epidermal growth factor receptor 
EP Etoposide/cisplatin 
ERBT External beam radiotherapy 
FDA US Food and Drug Administration 
FDG Fluorodeoxyglucose 
FGFR Fibroblast growth factor receptor 
Gy Gray 
HR Hazard ratio 
ICI Immune checkpoint inhibitor 
KRAS Kirsten Rat Sarcoma 
LACE Lung Adjuvant Cisplatin Evaluation 
LUAD Lung adenocarcinoma 
LUSC Lung squamous-cell carcinoma 
MAPK Mitogen-activated protein kinase 
MEK Mitogen-activated protein kinase kinase 
NOS Not otherwise specified 
NSCLC Non-small-cell lung carcinoma 
ORR Objective response rate 
OS Overall survival 
PC Carboplatin/paclitaxel 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed death-ligand 1 
PET Positron emission tomography 
PFS Progression-free survival 
PM2.5 Fine particulate matter 
RCT Randomized controlled trial 
ROS1 Proto-oncogene tyrosine-protein kinase ROS 
RR Risk ratio 
SBRT Stereotactic body radiation therapy 
SCLC Small-cell lung cancer 
SEER Surveillance, Epidemiology, and End Results 
Program 
TKI Tyrosine kinase inhibitor 
TNM TNM Classification of Malignant Tumors 
TP53 Tumor protein P53 
TPS Tumor proportion score 
VATS Video-assisted thoracoscopic surgery 
VEGF Vascular endothelial growth factor 
 
